

## Statement Affimed N.V. in relation to 2024 Annual General Meeting

Affimed N.V. has continued its stakeholder engagement in advance of its Annual General Meeting on June 26, 2024 (the "**2024 AGM**"). During this process of engagement, we have received input regarding the proposals to renew the authorizations of the Management Board to issue shares and to restrict and/or exclude pre-emptive rights (agenda items 9a and 9b of the 2024 AGM agenda).

Taking into account the feedback we have received from shareholders and other stakeholders with respect to the proposed authorizations described in the preceding paragraph, Affimed has decided to limit the proposed authorizations, both in terms of:

- (i) Volume: a limitation of up to 100% of the issued and outstanding share capital of the Company as per the date of the 2024 AGM (instead of the maximum number of shares that can be issued under the authorized share capital of the Company per the moment that the amendment of the articles of association as proposed under agenda item 8 of the 2024 AGM agenda becomes effective or, in case the proposal under agenda item 8 would not be adopted, as per the date of the 2024 AGM); and
- (ii) Authorization period: a limited period of 18 months from the 2024 AGM (instead of 5 years from the AGM date).

For Affimed as a Biotech company listed on Nasdaq, operating largely in environment of U.S. peers, it is essential to be able to raise capital in a similar manner as our U.S. peers. Affimed is of the opinion that the proposed authorizations are appropriate and required to execute its long-term strategy and to retain its ability to react in a timely manner when certain opportunities arise that require the issue of shares.

A revised version of the 2024 AGM agenda (and a redline reflecting the changes made compared to the original 2024 AGM agenda) has been made available on the Company's website.

Mannheim, Germany